We have begun analyzing our preliminary 2023 Integrated Delivery Network (IDN) survey data and have found that oncology pharmacists are once again looking forward to meeting manufacturer team members in person. Our 2022 research found providers still grappling with COVID-19 impacts and preferring virtual meetings. Now, with a better understanding of COVID and its effects, providers’ preferences are shifting toward in-person interactions, although virtual options remain in the mix.
Source: HMP Market Access Insights.
Abbreviations: HCP, health care professional.
We are now conducting our follow-up interviews, and beyond the survey findings the oncology pharmacists tell us:
Stay tuned for more insights and the publication of our 2023 IDN Oncology Trend Survey next month. Until then, please reach out with any comments or questions you may have.
In the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.
Lee BlansettBispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Chris Van DenburgIn part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the operational realities of oncology practice economics.
Lee Blansett